2nd Aug 2021 21:22
MaxCyte Inc - platform technologies provider for cell engineering - Underwriters of initial public offering in New York have elected to purchase 2.0 million shares at the IPO price of USD13 per share, raising around USD26.3 million in additional proceeds, bringing the total proceeds fro the offering to USD201.8 million.
MaxCyte will remain listed on London's AIM and will commence trading in New York on Wednesday.
Current stock price: 1,100 pence
Year-to-date change: up sharply from 527.50p
By Dayo Laniyan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
MaxCyte